I-$100M yokuthuthukisa Ukwelashwa Kwamasosha omzimba Kwezifo Ezinzima Nezingavamile Zokuzivikela Kumzimba

A BAMBA Ukukhululwa Kwamahhala | eTurboNews | eTN
Isithombe sikaLinda Hohnholz
Ibhalwe ngu Linda Hohnholz

I-Dianthus Therapeutics namuhla imemezele ukuphothulwa kwezimali zayo eziyizigidi eziyi-100 ze-Series A eziholwa yi-5AM Ventures, Avidity Partners, kanye ne-Fidelity Management & Research Company, ngokubamba iqhaza kwabatshalizimali abengeziwe okuhlanganisa i-Wedbush Healthcare Partners kanye nabasunguli abatshalizimali i-Fairmount, i-Tellus BioVentures, ne-Venrock Healthcare Capital Partners. . Uxhaso luzosetshenziswa ukuze kwandiswe abaholi namaqembu esayensi, kuthuthukiswe uhlelo oluholayo lwenkampani, i-DNTH103, emtholampilo kulo nyaka, kanye nokusheshisa izinhlelo ezengeziwe zokutholwa kwabantu abaphila nezifo ezinzima nezingavamile zokuzivikela komzimba. I-DNTH103 iyi-antibody ye-monoclonal enamandla, yesizukulwane esilandelayo eqondise ngokukhetha uhlobo olusebenzayo lwe-C1s ehambisanayo, engase inike amandla umthamo ophansi womthamo kanye nokuphatha okungaphansi kwesikhumba okungavamisile okuthuthukiswa ngokwengeziwe ngobuchwepheshe bokunwetshwa kwesigamu sempilo. 

UDianthus uphinde wamemezela ukuqokwa kukaMarino Garcia njengoMongameli kanye neSikhulu Esiphezulu, ojoyine ngoNovemba 2021, kanye noSimrat Randhawa, MD, MBA, njengeSikhulu Esiphezulu Sezokwelapha. UMnu. Garcia, umakadebona wokudayisa nosomaqhinga, uletha iminyaka engaphezu kwengu-25 yesipiliyoni sembonini ekuthuthukisweni kwebhizinisi kanye nezindima zobuholi bokusebenza ezinkampanini eziphezulu ze-biotech kanye nezamakhemisi, muva nje njengePhini Likamongameli Omkhulu, Ukuthuthukiswa Kwebhizinisi Nebhizinisi e-Zealand Pharma. UDkt. Randhawa uletha iminyaka engaphezu kwengu-20 yokusebenza komtholampilo kanye nolwazi lwemboni yezemithi ku-Dianthus, okuhlanganisa izindima zobuholi obuphezulu obugxile ku-autoimmune kanye nezikhala zezifo ezingandile. Muva nje usebenze njengePhini Likamongameli Omkhulu Wezindaba Zomtholampilo Nezokwelapha e-Aurinia Pharmaceuticals.

"Sizibophezele ekuthuthukiseni izimpilo zabantu abaphila nezifo ezinzima nezingavamile zokuzivikela komzimba futhi siyaqiniseka ukuthi amasosha ethu omzimba akhethiwe anamandla okuba yimithi yokwelapha ehamba phambili," kusho uMarino Garcia, uMongameli kanye neSikhulu Esiphezulu, i-Dianthus Therapeutics. “Sinenhlanhla yokuba neqembu eliqinile labatshalizimali abahamba phambili be-biotech, amalungu eBhodi anolwazi, nabaholi abaphumelele kanye nososayensi njengoba siqhubekisela phambili umuntu oholayo emtholampilo ngasekupheleni kwalo nyaka, sithuthukisa ipayipi lethu lokuthola izinto, futhi sandise ithimba lethu ezinyangeni ezizayo. . I-Dianthus ibekwe esikhundleni sokuba inkampani ehamba phambili, ehambisana nesizukulwane esilandelayo eqondiswa ukuqonda okujulile kwezidingo zeziguli. "

I-Dianthus ihlanganisa amandla okukhetha emigwaqweni ehambisanayo ukuze idale amasosha omzimba anamandla e-monoclonal anamandla okunqoba ukulinganiselwa kwemithi yokwelapha ehambisanayo yamanje. Ngokungafani nemithi yokwelapha yamanje yama-antibody ebophezela kukho kokubili amaprotheni ahambisanayo angasebenzi nasebenzayo, i-DNTH103 ngokukhetha iqondise kuphela uhlobo olusebenzayo lwe-C1s ehambisana namaprotheni, okuvumela umthamo ophansi wokudosa kanye nokuphatha kancane kancane. Ubuchwepheshe bayo bokunwetshwa kwesigamu sempilo nakho kunciphisa imvamisa yomthamo. Ngalezi zici ezihlukanisiwe kanye nokuvimbela amandla aphezulu e-C1s, i-DNTH103 iklanyelwe ukukhulula umthwalo wevolumu ephezulu, yokuphatha okuvamile nge-IV infusions noma ukuphazamiseka, ukudosa okuvamisile okungaphansi kwesikhumba. Ukusheshisa ukuthuthukiswa kwendlela yokwelapha engaphansi kwe-subcutaneous elula kungaba uguquko ekwandiseni iziguli ezingaba khona ezingazuza ekwelashweni okuhambisanayo, kuyilapho kunciphisa ukungakhululeki nokuphazamiseka okugcwele ezimpilweni zeziguli namuhla - ekugcineni kuvumela iziguli eziningi ukuthi ziphile impilo enempilo ngokugcwele. okungenzeka. 

"Siyaziqhenya ngokusekela i-Dianthus Therapeutics ekuthuthukiseni ukutholakala nokuthuthukiswa kwesizukulwane esilandelayo, i-antibody ehluke kakhulu yezokwelapha," kusho u-Paula Soteropoulos, uMqondisi Webhodi le-Dianthus kanye no-Strategic Advisor ku-5AM Ventures. “Ngobuholi bukaMongameli osanda qokwa kanye ne-CEO u-Marino Garcia, kanye nethimba elinethalente labaphathi be-biotech kanye nosomabhizinisi abanomlando omningi wempumelelo, sibheke ngabomvu ukubona i-Dianthus iletha izindlela zokwelapha ezintsha ezigulini ezinesifo esibucayi nesingavamile. izifo ze-autoimmune. ”

Mayelana umbhali

Isithombe sikaLinda Hohnholz

Linda Hohnholz

Umhleli omkhulu we eTurboNews ezinze eTN HQ.

Bhalisa
Yazisa ngakho
isivakashi
0 Amazwana
Okungaphakathi Okuphakelayo
Buka wonke amazwana
0
Ungathanda imibono yakho, ngicela uphawule.x
Yabelana ku...